GLP-1 digestive side effects often become less frequent over time. Nausea, vomiting and diarrhea commonly occur during dose increases. In one semaglutide study, individual episodes typically lasted days, while constipation lasted longer. There isn't a fixed week when everyone's symptoms end.
The most useful sign is whether symptoms are becoming less frequent and easier to manage. If they're worsening or making it hard to eat and drink, contact your prescriber. Our GLP-1 digestive side effects guide explains the common symptoms and warning signs.
Don't change your medication or dose without talking to your prescriber.
What the research says about duration
A pooled analysis of three semaglutide trials measured how long individual digestive side-effect events lasted. The studies used a weekly injection regimen targeting 2.4 mg in adults with overweight or obesity.
| Symptom | Median individual-event duration |
|---|---|
| Nausea | 8 days |
| Diarrhea | 3 days |
| Vomiting | 2 days |
| Constipation | 47 days |
Source: Wharton and colleagues, 2022; post-hoc pooled STEP 1-3 analysis, 2,117 adults assigned semaglutide and 1,262 placebo. These estimates apply to the studied 2.4 mg weekly injection regimen. They aren't duration estimates for other products, doses or tablet formulations.
These numbers describe single events, not the time until all symptoms settle. You could have nausea for a few days, feel better, then have another episode later. Short episodes can still affect your life over several weeks.
A median is the middle of an estimated distribution. Some events lasted less time and others lasted longer. It doesn't give you a personal deadline or a safe waiting period: repeated vomiting, dehydration and severe pain need attention promptly. Painful or difficult constipation also warrants advice well before 47 days.
How the timing compares across medicines
The labels describe a similar overall pattern: digestive side effects occur more often during dose escalation, when a prescriber gradually increases the dose. Some trial programs also report fewer nausea, vomiting and diarrhea events as treatment continues. The cited labels give no fixed symptom duration; the semaglutide analysis above provides separate episode data.
| Product and label revision | What the label says about timing |
|---|---|
| Wegovy, June 2026 | Gastrointestinal reactions in the adult injection program occurred most frequently during escalation |
| Zepbound, August 2026 | Most nausea, vomiting and diarrhea events in the weight-reduction trials occurred during escalation and decreased over time |
| Mounjaro, August 2026 | Most nausea, vomiting and diarrhea events in the type 2 diabetes trials occurred during escalation and decreased over time |
| Ozempic injection, May 2026 | Most nausea, vomiting and diarrhea occurred during escalation in the cited type 2 diabetes trials |
| Rybelsus/Ozempic tablets, January 2026 | Most nausea, vomiting and diarrhea occurred during escalation in the cited Rybelsus-formulation trials |
| Foundayo, July 2026 | Nausea, vomiting and diarrhea were more frequent during escalation and decreased over time |
Sources: linked US prescribing information, section 6.1, checked September 29, 2026. Findings apply to the named trial programs. Foundayo's label uses equivalent marketed doses to describe trials of an investigational formulation. Product and dose details identify research groups only.
A comfortable first week doesn't rule out symptoms after a later prescribed increase. Equally, a difficult start doesn't tell you how long symptoms will continue. Tell your prescriber about the pattern you're experiencing, including symptoms that begin after a settled period.
What to do if symptoms aren't settling
Contact your prescriber if symptoms recur, worsen, or interfere with meals, sleep or normal activities. A GLP-1 expert consensus recommends assessing other causes when digestive problems persist. The review can include your medicine, nutrition and other medications.
Keep a short record for the appointment:
Which symptoms occur and when they began, including any recent prescribed change.
Whether they're continuous or come in separate episodes.
What you're able to eat and drink, and whether you're urinating less.
How they affect your day, plus any other medicines, supplements or recent illness.
A few clear examples are enough. Ask what improvement to look for, when to check back, and how to contact the practice if symptoms worsen.
While arranging advice, eat slowly, choose smaller portions and stop at comfortable fullness. Avoid lying down after meals. The expert consensus recommends these measures to make digestive symptoms easier to manage.
With diarrhea or vomiting, replace lost fluids and electrolytes. NIDDK's diarrhea guidance includes oral rehydration solutions. Ask a pharmacist or clinician about a suitable product if you have diabetes, kidney disease or a fluid restriction.
Contact a doctor right away for diarrhea lasting more than two days, six or more loose stools a day, or high fever. Seek help sooner for dehydration or severe symptoms, regardless of the three-day study median.
For symptom-specific steps, see our diarrhea, constipation and sulfur-burp guides.
Where gut-brain support fits
If you had recurring digestive symptoms before starting your medicine, include that history in the conversation. An existing gut-brain condition can need attention alongside a new medication-related problem.
Nerva gives you a daily gut-brain practice through guided hypnotherapy audio, breathing exercises and education. Its trial evidence is in IBS; it hasn't been shown to shorten GLP-1 side effects.
Read about gut-brain approaches or explore Nerva.
Symptoms that shouldn't wait
When to get medical help
Call 911 for chest pain, trouble breathing, fainting or collapse.
Get medical help right away for severe or lasting abdominal pain, especially if it spreads to your back; vomiting blood or black or bloody stools; repeated vomiting, inability to keep fluids down or very little urine; a swollen, painful belly with inability to pass stool or gas; or upper-right abdominal pain with fever or yellow skin or eyes.
Trouble swallowing needs prompt medical assessment. If you can't swallow at all, go to an emergency department.
Sources: medication warnings, NIDDK, CDC and Mayo Clinic.
Does feeling sick mean the medicine is working better?
No. In the pooled STEP analysis, semaglutide's weight-loss effect was largely independent of gastrointestinal side effects.
Ozempic, Wegovy and Rybelsus are trademarks of Novo Nordisk. Mounjaro, Zepbound and Foundayo are trademarks of Eli Lilly. Nerva is not affiliated with either company.
References
Novo Nordisk. Wegovy (semaglutide) US prescribing information. Revised June 2026. Sections 6.1 and 12. https://www.novo-pi.com/wegovy.pdf
Eli Lilly and Company. Zepbound (tirzepatide) US prescribing information. Revised August 2026. Section 6.1. https://pi.lilly.com/us/zepbound-uspi.pdf
Eli Lilly and Company. Mounjaro (tirzepatide) US prescribing information. Revised August 2026. Section 6.1. https://pi.lilly.com/us/mounjaro-uspi.pdf
Novo Nordisk. Ozempic (semaglutide) injection US prescribing information. Revised May 2026. Section 6.1. https://www.novo-pi.com/ozempic.pdf
Eli Lilly and Company. Foundayo (orforglipron) US prescribing information. Revised July 2026. Sections 6.1 and 12. https://pi.lilly.com/us/foundayo-uspi.pdf
Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94-105. doi:10.1111/dom.14551. https://pmc.ncbi.nlm.nih.gov/articles/PMC9293236/
Novo Nordisk. Rybelsus (semaglutide) tablets and Ozempic (semaglutide) tablets US prescribing information. Revised January 2026. Section 6.1. https://www.novo-pi.com/rybelsus.pdf
Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145. Published online December 24, 2022. doi:10.3390/jcm12010145. https://pmc.ncbi.nlm.nih.gov/articles/PMC9821052/
National Institute of Diabetes and Digestive and Kidney Diseases. Treatment of diarrhea. Accessed September 29, 2026. https://www.niddk.nih.gov/health-information/digestive-diseases/diarrhea/treatment
National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms & causes of diarrhea. Accessed September 29, 2026. https://www.niddk.nih.gov/health-information/digestive-diseases/diarrhea/symptoms-causes
National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms & causes of gas in the digestive tract. Reviewed June 2021. https://www.niddk.nih.gov/health-information/digestive-diseases/gas-digestive-tract/symptoms-causes
National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms & causes of gastroparesis. Reviewed January 2018. https://www.niddk.nih.gov/health-information/digestive-diseases/gastroparesis/symptoms-causes
Mindset Health. Nerva for clinicians. Existing program mechanics and eligibility; accessed September 29, 2026. https://www.nervahealth.com/clinicians
Centers for Disease Control and Prevention. About Heart Attack Symptoms, Risk, and Recovery. https://www.cdc.gov/heart-disease/about/heart-attack.html
Mayo Clinic. Difficulty swallowing in adults: when to seek medical advice. https://www.mayoclinic.org/symptom-checker/difficulty-swallowing-in-adults-adult/related-factors/itt-20009075
